These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12099151)

  • 1. Double-blind, randomised, placebo controlled low level laser therapy study in patients with primary Raynaud's phenomenon.
    Hirschl M; Katzenschlager R; Ammer K; Melnizky P; Rathkolb O; Kundi M
    Vasa; 2002 May; 31(2):91-4. PubMed ID: 12099151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low level laser therapy in primary Raynaud's phenomenon--results of a placebo controlled, double blind intervention study.
    Hirschl M; Katzenschlager R; Francesconi C; Kundi M
    J Rheumatol; 2004 Dec; 31(12):2408-12. PubMed ID: 15570642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low level laser therapy for treatment of primary and secondary Raynaud's phenomenon.
    al-Awami M; Schillinger M; Maca T; Pollanz S; Minar E
    Vasa; 2004 Feb; 33(1):25-9. PubMed ID: 15061044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low level laser treatment of primary and secondary Raynaud's phenomenon.
    al-Awami M; Schillinger M; Gschwandtner ME; Maca T; Haumer M; Minar E
    Vasa; 2001 Nov; 30(4):281-4. PubMed ID: 11771213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon.
    Kyle MV; Belcher G; Hazleman BL
    J Rheumatol; 1992 Sep; 19(9):1403-6. PubMed ID: 1279169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon.
    Whitmore SE; Wigley FM; Wise RA
    J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thermographic parameters in the diagnosis of secondary Raynaud's phenomenon.
    Schuhfried O; Vacariu G; Lang T; Korpan M; Kiener HP; Fialka-Moser V
    Arch Phys Med Rehabil; 2000 Apr; 81(4):495-9. PubMed ID: 10768542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.
    Teh LS; Manning J; Moore T; Tully MP; O'Reilly D; Jayson MI
    Br J Rheumatol; 1995 Jul; 34(7):636-41. PubMed ID: 7670782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infrared thermography in the diagnosis of Raynaud's phenomenon in vibration-induced white finger.
    von Bierbrauer A; Schilk I; Lucke C; Schmidt JA
    Vasa; 1998 May; 27(2):94-9. PubMed ID: 9612113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon.
    Wollersheim H; Thien T; Fennis J; van Elteren P; van 't Laar A
    Clin Pharmacol Ther; 1986 Aug; 40(2):219-25. PubMed ID: 3731684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isosorbide dinitrate ointment in Raynaud's disease.
    Diehm C; Müller-Bühl U; Mörl H
    Z Kardiol; 1983; 72 Suppl 3():185-7. PubMed ID: 6364591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A; McCans J; Willan AR; Ford PM
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.